BioSpace News Archive

Biometric screening gives early warning on health, improves productivity, morale

Shares of Paris-based GenSight plunged nearly 19 percent Monday after the company announced that its gene therapy for Leber hereditary optic neuropathy (LHON) failed to show a significant effect in patients at 48 weeks.

As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. What are the unique benefits your life sciences employer offers?

According to WARN notices, the two companies will slash a total of 106 jobs starting in March.

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that ModernaTX, Inc. has exercised its option to enter into an exclusive licensing agreement with respect to certain Affimers against a potential therapeutic target that has been part of an ongoing research collaboration between the two companies.

Paras Biopharmaceuticals Finland Oy announced the achievement of a major milestone – the successful development of biologically active Romiplostim production technology.

Scarab Genomics LLC and Theraly Fibrosis Inc. announced that they have entered into a license agreement to allow Theraly Fibrosis to fully exploit Scarab Genomics’ technology for the production of a protein for its core therapeutic program.

Sirion Biotech International threw a Bavarian-themed grand opening party at the Forsythe Institute on Feb. 1. The new headquarters are in Cambridge, Mass and currently have five employees.

Last week HHS floated a plan that would allow companies to pass rebates of 26 to 30 percent of a drug’s list price directly to patients in order to be reflected in what consumers pay at the pharmacy counter.

The two Phase III trials are part of a five-trial package the companies are conducting to support potential regulatory approval for this indication.